Technological watch
Purolite and Repligen launch resin for purification of specialised mAbs
Purolite, an Ecolab company and manufacturer of synthetic and agarose-based bioprocessing resins, has launched Praesto CH1, a new 70?m (micron) agarose-based affinity resin designed to purify specialised mAbs such as bispecifics and recombinant antibody fragments.
× Rawpixel.com Shutterstock
Rocket ship launch teamwork concept
This latest innovation, which was developed for commercialisation by Purolite as part of a multi-year strategic partnership with Repligen, combines Purolite’s patented Jetted beads manufacturing process with Repligen’s leading ligand technology to address previously unmet challenges in specialised mAb purification.
The new CH1 purification resin builds on the success of Purolite’s current protein A resin portfolio, demonstrating high selectivity for antibodies and related fragments containing the human CH1 domain. This allows for the capture of bispecific antibodies and antibody fragments, as well as the removal of mis-paired species, providing an effective alternative for the purification of antibody variants when Protein A resins are not suitable.
Purolite’s vice president of research and development, Jennifer Sorrells, said: “The launch of Praesto CH1 represents the latest offering in Purolite’s growing innovation toolbox for the purification of biologics. Our strategic partnership with Repligen brings technologies together to unlock new purification strategies that address our customers’ increasingly diverse biotherapeutic molecules, and the unique purification challenges that these can present."
The announcement of Purolite’s latest resin innovation reinforces the company’s commitment to product expansion and innovation and follows news of its investment in a new bioprocessing production facility based in Landenberg, PA. The new production facility will be Purolite’s fourth location in Pennsylvania, further solidifying its commitment to meeting the needs of customers globally by providing dual-continent agarose manufacturing.
Back to Search Results Tags Purolite Repligen resin collaboration
× Rawpixel.com Shutterstock
Rocket ship launch teamwork concept
This latest innovation, which was developed for commercialisation by Purolite as part of a multi-year strategic partnership with Repligen, combines Purolite’s patented Jetted beads manufacturing process with Repligen’s leading ligand technology to address previously unmet challenges in specialised mAb purification.
The new CH1 purification resin builds on the success of Purolite’s current protein A resin portfolio, demonstrating high selectivity for antibodies and related fragments containing the human CH1 domain. This allows for the capture of bispecific antibodies and antibody fragments, as well as the removal of mis-paired species, providing an effective alternative for the purification of antibody variants when Protein A resins are not suitable.
Purolite’s vice president of research and development, Jennifer Sorrells, said: “The launch of Praesto CH1 represents the latest offering in Purolite’s growing innovation toolbox for the purification of biologics. Our strategic partnership with Repligen brings technologies together to unlock new purification strategies that address our customers’ increasingly diverse biotherapeutic molecules, and the unique purification challenges that these can present."
The announcement of Purolite’s latest resin innovation reinforces the company’s commitment to product expansion and innovation and follows news of its investment in a new bioprocessing production facility based in Landenberg, PA. The new production facility will be Purolite’s fourth location in Pennsylvania, further solidifying its commitment to meeting the needs of customers globally by providing dual-continent agarose manufacturing.
Back to Search Results Tags Purolite Repligen resin collaboration
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 870292.
